BiotechTube

Eloralintide and Tirzepatide + Eloralintide

Phase 1Completed
0 views this week 0 watching💤 Quiet
Interest: 29/100
29
Hype Score

Development Stage

✓
Pre-clinical
2
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Overweight

Conditions

Overweight, Obesity

Trial Timeline

Apr 9, 2025 → Jan 19, 2026

NCT ID
NCT06916065

About Eloralintide and Tirzepatide + Eloralintide

Eloralintide and Tirzepatide + Eloralintide is a phase 1 stage product being developed by Eli Lilly for Overweight. The current trial status is completed. This product is registered under clinical trial identifier NCT06916065. Target conditions include Overweight, Obesity.

What happened to similar drugs?

1 of 20 similar drugs in Overweight were approved

Approved (1) Terminated (0) Active (19)
✅AripiprazoleBristol Myers SquibbApproved
🔄Eloralintide + PlaceboEli LillyPhase 3
🔄Eloralintide + PlaceboEli LillyPhase 3
🔄Tirzepatide + PlaceboEli LillyPhase 3
🔄Tirzepatide + PlaceboEli LillyPhase 3
🔄Maridebart cafraglutide + PlaceboAmgenPhase 3
🔄Semaglutide + Semaglutide PlaceboNovo NordiskPhase 3

Hype Score Breakdown

Clinical
6
Activity
8
Company
15
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT06916065Phase 1Completed

Competing Products

20 competing products in Overweight

See all competitors
ProductCompanyStageHype Score
TERN-601Terns PharmaceuticalsPhase 2
32
LY3457263 + Tirzepatide + PlaceboEli LillyPhase 1
29
LY3305677 + PlaceboEli LillyPhase 1
29
LY3537031 + PlaceboEli LillyPhase 1
33
Tirzepatide + Lisdexamfetamine Dimesylate + Placebo (oral) + Placebo (injection)Eli LillyPhase 2
42
Eloralintide + PlaceboEli LillyPhase 3
47
LY4064912 + LY4064912 + Placebo + PlaceboEli LillyPhase 1
36
LY3437943 + Ethinyl Estradiol + DrospirenoneEli LillyPhase 1
29
Tirzepatide + AcetaminophenEli LillyPhase 1
29
Tirzepatide + PlaceboEli LillyPhase 2
39
Eloralintide + PlaceboEli LillyPhase 3
47
LY3437943 + PlaceboEli LillyPhase 1
29
LY3502970 + PlaceboEli LillyPhase 1
29
Tirzepatide + PlaceboEli LillyPhase 3
44
Tirzepatide + PlaceboEli LillyPhase 3
40
LY3541105 + PlaceboEli LillyPhase 1
29
Retatrutide + PlaceboEli LillyPhase 2
35
LY4167586 + Placebo + LY4167586Eli LillyPhase 1
36
AZD9550 + AZD6234 + Placebo comparatorAstraZenecaPhase 2
39
pramlintide acetate + sibutramine + phentermine + placeboAstraZenecaPhase 2
35